

**Title of the trial:** A phase I / randomized phase II trial to analyse safety and efficacy of human SARS-CoV-2-specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 [ACT-COVID19]  
**Protocol code number:** Uni-Köln-4480  
**EudraCT number:** 2021-000417-16

---

## **Notification of the end of a clinical trial**

The clinical trial was terminated on August, 03 by the sponsor representative. The reason for the premature termination is the poor enrollment of patients in the ACT-COVID19 trial.

So far, only one patient has been enrolled in the trial. However, this patient dropped out before IMP was administered.

As no patient has received study medication, there are no usable data to evaluate the results.